Rebiotix is working closely with the U.S. FDA as it conducts an advanced clinical research program

Clinical Trials

Rebiotix has conducted several clinical trials with it’s lead microbiota-based product in the MRT™ drug platformRBX2660 for the prevention of recurrent Clostridium difficile (C. diff) infection, and is currently enrolling in a Phase 3  clinical trial,  in conjunction with the U.S Food and Drug Administration under an Independent New Drug Application.

For currently enrolling clinical trials, go to

Important milestones include:

Special FDA designations for RBX2660: